...
机译:支持对炎症性肠病患者的vedolizumab槽浓度进行支持的证据
Laboratory for Therapeutic and Diagnostic Antibodies Department of Pharmaceutical and;
Translational Research in GastroIntestinal Disorders Department of Clinical and Experimental;
Laboratory for Therapeutic and Diagnostic Antibodies Department of Pharmaceutical and;
Translational Research in GastroIntestinal Disorders Department of Clinical and Experimental;
Laboratory for Therapeutic and Diagnostic Antibodies Department of Pharmaceutical and;
Laboratory for Therapeutic and Diagnostic Antibodies Department of Pharmaceutical and;
Department of Gastroenterology and Hepatology University Hospitals Leuven KU Leuven – University;
Translational Research in GastroIntestinal Disorders Department of Clinical and Experimental;
Translational Research in GastroIntestinal Disorders Department of Clinical and Experimental;
Laboratory for Therapeutic and Diagnostic Antibodies Department of Pharmaceutical and;
Translational Research in GastroIntestinal Disorders Department of Clinical and Experimental;
Monoclonal Antibody; Integrin; Pharmacokinetics; Therapeutic Drug Monitoring;
机译:支持对炎症性肠病患者的vedolizumab槽浓度进行支持的证据
机译:具有Meta分析的系统审查:炎症肠疾病患者的Vedolizumab槽浓度和临床结果之间的关联
机译:维持治疗期间的高谷Vedolizumab浓度与炎性肠病的皮质类固醇缓解有关
机译:炎症性肠病患者的发病率增加了与免疫调节治疗有关的发病危险
机译:肠道制剂对健康受试者中结肠菌细菌植物菌的影响和炎症性肠病患者
机译:Vedolizumab血清槽浓度和对炎症性肠病剂量升级的反应
机译:P518 Vedolizumab槽浓度与炎症性肠病患者的内窥镜反应有关